AI 34853/AI/NIAID NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2004	1
2005	1
2006	3
2007	5
2008	1
2009	2
2010	2
2011	3
2013	1
2014	1
2024	0

1

Changes in weight and lean body mass during highly active antiretroviral therapy.

Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, Evans S, Mulligan K; AIDS Clinical Trial Group 892 Team. Shikuma CM, et al. Clin Infect Dis. 2004 Oct 15;39(8):1223-30. doi: 10.1086/424665. Epub 2004 Sep 27. Clin Infect Dis. 2004. PMID: 15486848 Clinical Trial.

2

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team. Gulick RM, et al. J Infect Dis. 2007 Jul 15;196(2):304-12. doi: 10.1086/518797. Epub 2007 Jun 5. J Infect Dis. 2007. PMID: 17570119 Clinical Trial.

3

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.

Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, Giuliano M, Dehlinger M, Garren K, Brizz B, Bassett R. Fischl MA, et al. AIDS. 2007 Jan 30;21(3):325-33. doi: 10.1097/QAD.0b013e328011ddfa. AIDS. 2007. PMID: 17255739 Clinical Trial.

4

Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation.

Hulgan T, Stein JH, Cotter BR, Murdock DG, Ritchie MD, Dube MP, Gerschenson M, Haas DW, Torriani FJ; Aids Clinical Trials Group A5152s And Dacs 252 Study Teams. Hulgan T, et al. AIDS Res Hum Retroviruses. 2013 Oct;29(10):1293-9. doi: 10.1089/aid.2013.0079. Epub 2013 Aug 14. AIDS Res Hum Retroviruses. 2013. PMID: 23944767 Free PMC article. Clinical Trial.

5

European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.

Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA. Hulgan T, et al. AIDS. 2011 Jan 2;25(1):37-47. doi: 10.1097/QAD.0b013e32833f9d02. AIDS. 2011. PMID: 20871389 Free PMC article.

6

A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.

Demeter LM, Jiang H, Mukherjee AL, Morse GD, DiFrancesco R, DiCenzo R, Dykes C, Sista P, Bacheler L, Klingman K, Rinehart A, Albrecht M. Demeter LM, et al. AIDS. 2009 Jan 28;23(3):357-68. doi: 10.1097/QAD.0b013e32831f9148. AIDS. 2009. PMID: 19114860 Free PMC article. Clinical Trial.

7

Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.

Weinberg A, Tierney C, Kendall MA, Bosch RJ, Patterson-Bartlett J, Erice A, Hirsch MS, Polsky B; AIDS Clinical Trials Group 360 Team. Weinberg A, et al. J Infect Dis. 2006 Feb 15;193(4):488-93. doi: 10.1086/499826. Epub 2006 Jan 3. J Infect Dis. 2006. PMID: 16425127

8

Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.

Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. Bosch RJ, et al. J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):268-77. doi: 10.1097/QAI.0b013e31802c7e20. J Acquir Immune Defic Syndr. 2007. PMID: 17146370 Clinical Trial.

9

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, Pilcher C, Zolopa A, Lawrence J, Pollard RB, Habib RE, Sahner D, Fox L, Aga E, Bosch RJ, Mitsuyasu R; Adult AIDS Clinical Trials Group A5024 Protocol Team. Kilby JM, et al. J Infect Dis. 2006 Dec 15;194(12):1672-6. doi: 10.1086/509508. Epub 2006 Nov 8. J Infect Dis. 2006. PMID: 17109338 Clinical Trial.

10

Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration.

Martin BK, Wu AW, Gelman R, Mitsuyasu RT; Adult AIDS Clinical Trials Group. Martin BK, et al. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):428-33. doi: 10.1097/01.qai.0000182848.45722.b7. J Acquir Immune Defic Syndr. 2005. PMID: 16280697 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

20 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year